Ruxolitinib

Routes
Oral (PO)
Half-Life (t½)
PO: 3h
Formula
C17H18N6
Molecular Weight
306.36 g/mol
PubChem CID
25126798
Aliases
Jakafi, Jakavi, INCB018424

Pharmacological Mechanism

JAK1/JAK2 inhibitor — first JAK inhibitor approved (2011). Indications: myelofibrosis, polycythemia vera (HU-resistant), steroid-refractory acute + chronic GVHD. CYP3A4 substrate. Discontinuation of ruxolitinib in MF requires a slow taper to avoid cytokine-rebound systemic inflammatory response. PK (Jakafi label, 20 mg PO bid IR): Cmax 205-7100 nM across single-dose range (linear), Tmax 1-2 h, F ≥95%, t½ 3.0 h IR formulation (5.4 h newer ER once-daily formulation), Vss 72 L. CYP3A4 substrate; no significant food effect.

Half-Life & Elimination Curve (PO: 3h)

100%50%25%12.5%0%0h0×t½3h1×t½6h2×t½9h3×t½12h4×t½15h5×t½0×t½ (0h): 100% remaining (~0.17 mg/L)1×t½ (3h): 50% remaining (~85 µg/L)2×t½ (6h): 25% remaining (~42.5 µg/L)3×t½ (9h): 12.5% remaining (~21.2 µg/L)4×t½ (12h): 6.3% remaining (~10.6 µg/L)5×t½ (15h): 3.1% remaining (~5.31 µg/L)
Plasma (PO)t½ Decay (3h)
  • 0×t½0h100% (0.17 mg/L)
  • 1×t½3h50% (85 µg/L)
  • 2×t½6h25% (42.5 µg/L)
  • 3×t½9h12.5% (21.2 µg/L)
  • 4×t½12h6.3% (10.6 µg/L)
  • 5×t½15h3.1% (5.31 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)1.91h
Est. Peak (Cmax)0.17 mg/L
Clearance (CL)16.6 L/h
97% Washout (5×t½)15h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References